Overview
- Isomorphic announced the oversubscribed $5 billion Series C on Tuesday, November 17, 2026, saying the round was co‑led by Greenoaks and Sequoia with participation from Andreessen Horowitz and continued significant investment from Alphabet.
- The company said proceeds will be used to mature IsoDDE, a unified suite of simulation AI models that design and refine drug molecules before lab tests, and to build global AI‑led bioengineering and translational infrastructure.
- Isomorphic reported positive preclinical results in internal oncology and immunology programs and in partner work that it says set the stage for clinical entry, though it has not disclosed timelines or regulatory milestones required for human trials.
- The financing preserves close ties to Alphabet and complements commercial partnerships listed on Isomorphic’s site with Novartis, Eli Lilly and Johnson & Johnson to help develop and advance candidates outside the company.
- The round follows a $2.1 billion Series B roughly six months earlier and reflects a wider 2026 surge of investor capital into AI drug discovery that could speed how quickly lab‑tested molecules reach patients if translational and regulatory steps succeed.